Testosterone in Women's HRT: the case most clinics miss

By the time a woman reaches her mid-40s, her circulating testosterone is roughly half what it was in her 20s. That decline is quiet, gradual, and — in most menopause clinics — completely ignored. Estrogen and progesterone get the attention. Testosterone gets a shrug.

That's a problem, because the data on testosterone in women is more mature than most patients realize. There is an international consensus statement, randomized trials, and a defined therapeutic window. What there isn't, in the United States, is an FDA-approved female testosterone product — which is the real reason most clinics don't offer it.

Why testosterone matters in female physiology — in plain English

Testosterone isn't a "male" hormone. Women produce it in the ovaries and adrenal glands, and across the reproductive years, they make about three times more testosterone than estradiol by mass. It circulates, binds androgen receptors, and also serves as a substrate the body converts into estradiol via aromatase.

Production peaks in a woman's 20s and declines steadily with age. By natural menopause, total testosterone is meaningfully lower than premenopausal baseline. Surgical menopause — bilateral oophorectomy — causes an abrupt drop of roughly 50% almost overnight.

The symptoms that follow are not subtle to the women experiencing them: loss of sexual desire, reduced arousal and orgasm intensity, flatter mood, and a sense that the internal engine has cooled. Estrogen replacement alone often doesn't fully address these.

What the evidence actually shows — the honest read

The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed by the Endocrine Society, International Menopause Society, and several other bodies, concluded that the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder (HSDD) in postmenopausal women.

That sounds narrow, and clinically it is — but the data behind it is solid:

• Multiple randomized, placebo-controlled trials (the APHRODITE program, the Davis trials) showed that transdermal testosterone at physiologic doses increased the number of satisfying sexual events, desire scores, and arousal in postmenopausal women with HSDD.
• Effect sizes were modest but real, and the safety signal at physiologic dosing was clean over 6–12 month trials.
• Benefits on mood, cognition, musculoskeletal health, and body composition are biologically plausible but not yet supported by the same tier of evidence. The consensus statement is explicit about this distinction.

So the honest read is: for postmenopausal HSDD, testosterone is evidence-based. For everything else women report improving on it, the mechanism is reasonable but the trial evidence is thinner.

Why most clinics still don't prescribe it

Three reasons, and none of them are "it doesn't work."

1. There is no FDA-approved female testosterone product in the U.S. Every prescription written for a woman is technically off-label — either a fraction of a male-approved gel, or a compounded cream. Many clinicians are uncomfortable with off-label prescribing in an area they weren't trained in.

2. Training gap. Most OB/GYN and primary care residencies devote almost no time to androgen physiology in women. If you weren't taught it, you don't prescribe it.

3. Lab interpretation is genuinely harder in women. Standard total testosterone assays were designed for the male range and lose accuracy at the low concentrations relevant in women. Liquid chromatography–mass spectrometry (LC-MS/MS) is the preferred method, and not every lab defaults to it.

None of these are reasons the therapy is wrong. They're reasons the system is slow.

Testosterone deficiency in women is not a fringe complaint — it's a mainstream physiologic reality that mainstream medicine hasn't caught up to.

What a thoughtful workup looks like — tuned to your numbers

Before starting testosterone, the labs worth having on the table typically include:

• Total testosterone (ideally LC-MS/MS)
• SHBG (sex hormone-binding globulin — high SHBG binds testosterone and drops free levels)
• Free testosterone, calculated or measured
• Estradiol and FSH to characterize menopausal status
• DHEA-S as an adrenal androgen marker
• CBC, lipid panel, and a metabolic panel as safety baselines

The goal of therapy is to restore testosterone into the upper end of the premenopausal physiologic range — not above it. Supraphysiologic dosing is where the side effects (acne, hair changes, voice changes, virilization) live, and those changes can be slow to reverse.

{callout: The takeaway} Testosterone therapy in women has the strongest evidence for postmenopausal HSDD, works best when dosed to restore — not exceed — the premenopausal physiologic range, and requires the right assay to monitor safely.

Dosing and delivery — the standard published ranges

International consensus supports transdermal delivery (cream or gel) as the preferred route, because it avoids the hepatic first-pass effect and gives smoother pharmacokinetics than injections or pellets.

Published consensus dosing targets approximately one-tenth of a typical male replacement dose, titrated to keep total testosterone within the premenopausal reference range. Oral testosterone is not recommended because of adverse effects on lipids. Pellets are used in some practices but produce higher peak levels and less dose flexibility — the consensus statement recommends against them for this reason.

Monitoring after initiation typically includes a repeat testosterone level at 6–8 weeks, then every 6 months once stable, along with a check-in on side effects (skin, hair, mood, cycle irregularity if perimenopausal).

Who is — and isn't — a candidate

Reasonable candidates, based on current evidence:

• Postmenopausal women (natural or surgical) with distressing low sexual desire, after other contributors (relationship, medication side effects, depression, thyroid, estrogen deficiency) have been addressed.
• Women already on estrogen replacement who still report androgen-deficiency symptoms.

Groups where evidence is weaker or caution is warranted:

• Premenopausal women — trial data is limited, and cycle disruption is a real risk.
• Women with androgen-sensitive cancers, active liver disease, or untreated significant hyperlipidemia.
• Women pursuing testosterone primarily for weight loss or athletic performance — this is not what the evidence supports, and the dose creep required to chase those effects is where harm shows up.

The trade-offs, stated plainly

At physiologic doses, the side effect profile in trials was similar to placebo, with mild acne and increased body hair being the most common. At supraphysiologic doses, deeper concerns emerge: voice changes, clitoral enlargement, scalp hair thinning, adverse lipid shifts. Some of these are not fully reversible.

Long-term cardiovascular and breast safety data beyond 24 months is limited. The consensus statement is candid: we have strong short-term safety data and reasonable biological plausibility for long-term safety at physiologic dosing, but we do not have 10-year randomized outcomes.

That's the honest state of the field. It's also true of a lot of therapies women are routinely offered.

What this means for your protocol

If you're on estrogen and progesterone and still feel like something's missing — desire, drive, the sense of aliveness — testosterone is a reasonable conversation to have with a clinician who actually knows the female androgen literature. Not every symptom is a testosterone problem, but ruling it out with a proper assay and an informed discussion is a very different experience from being told "women don't need testosterone."

The compounded testosterone products used in female HRT are not FDA-approved as finished products — see our disclaimer for what that means in practice. What matters clinically is the dose, the delivery route, the monitoring, and whether the clinician prescribing it understands where physiologic ends and supraphysiologic begins.

That line is where the benefit lives. Cross it, and the therapy stops being replacement and starts being something else.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.